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ASSOCIATION BETWEEN MORTALITY AND VISUAL
IMPAIRMENT ESTIMATED FROM A FRENCH NATIONAL
SURVEY
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1Hopital Cochin, Paris, France; 2Cemka, Bourg-La-Reine, France;
3Université de Bretagne-Sud,Vannes, France; 4Alcon, Rueil-Malmaison,
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OBJECTIVES: To estimate the association between visual
impairment (expressed as low vision (LV) and blindness) and
mortality. METHODS: Two national surveys were pooled
together. First, 2075 institutions for children or adults with
handicaps, the aged, and psychiatric patients were selected at
random, in 18 predeﬁned strata, from French Health Ministry
ﬁles. In total, 15,403 subjects were selected and 14,603 (94.9%)
were interviewed. Second, a random, stratiﬁed sample of
356,208 persons living in the community was selected, of whom
21,760 subjects were further selected, randomly, and 16,945
(77.9%) were interviewed. Three groups were identiﬁed, based
on personal interviews: blind, LV, and a control group (CG). Two
years later, 14,497 subjects in institutions and 15,648 in the com-
munity were questioned again. Data on death were obtained
from either the national register or households. Death rates were
estimated by age, gender and visual impairment. Weights for
national extrapolation came from the 1999 national census. A
logistic stepwise regression was used to adjust for other handi-
caps, activity of daily living (ADL), age-squared by gender inter-
action, and institution versus community residence. RESULTS:
The average age of subjects was 38.3 years, 48.60% were male
and 1.15% lived in institutions. The death rate (1.76% over 2
years) increased exponentially with age and male gender. This
last interaction explained most of the variance and ADL
accounted for the balance. The probability of dying was higher
in subjects with handicaps: visceral (odds ratio[OR] = 2.83),
speech (OR = 2.10), brain (OR = 1.53), motor function (OR =
1.42), or auditory (OR = 1.39). Visual impairment was signiﬁ-
cantly (p < 0.0001) associated with increased risk of mortality
(blindness: OR = 2.79; LV: OR = 2.06). CONCLUSIONS: Visual
impairment is an independent factor associated with mortality.
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ANALYSIS OF CLINICAL EFFICACY OF LATANOPROST VS.
THE MOST FREQUENT TREATMENT PATTERN FOR PRIMARY
OPEN ANGLE GLAUCOMA (POAG) AND OCULAR
HYPERTENSION (OH) IN POLAND
Walczak J1, Pajor A1, Kaczor M1,Wcislo J2
1Arcana Institute, Krakow, Poland; 2Pﬁzer, Warsaw, Poland
OBJECTIVES: The aim of the study was comparing latanoprost
treatment with the most frequent therapy pattern for POAG and
OH in Poland. The most frequently prescribed drug for treat-
ment of POAG and OH in Poland is dorzolamide, representing
30% of total prescriptions. Approximately 25% of prescriptions
for POAG represent dorzolamide in polytherapy, the most fre-
quent combination with timolol represents 9% of total pre-
scriptions. METHODS: We assessed current treatment patterns
of POAG and OH based on IMS Health Data from Poland
(MAT/ September, 2003). The clinical efﬁcacy analysis was based
on the systematic review in accordance with methodological
survey rules based on Cochrane Reviewer’s Handbook. Data
were extracted from the randomized controlled trials comparing
latanoprost 0.005% once daily vs. dorzolamide t.i.d. and
latanoprost 0.005% vs. dorzolamide 2% + timolol 0.5% b.i.d.
and entered into the Review Manager computer software.
Response to treatment was estimated in accordance with meta-
analysis trials, which included Odds Ratio of the observation of
minimum 10%, 20%, 30%, 40% IOP reduction in relation to a
starting level after 3 months treatment. RESULTS: In a group of
patients treated with latanoprost, the chance of 20%, 30%, 40%
IOP reduction in relation to baseline was statistically higher than
in dorzolamide group in monotherapy: (20% OR = 7.1; 95% CI
3.1 to 59,5), (30% OR = 6.5; 95% CI 3.3 to 12.6), (40% OR
= 7.1; 95% CI 3.6 to 13.9) and also in comparison with com-
bined therapy group (20% OR = 1.7; 95% CI 1.1 to 2.4), (30%
OR = 1.4; 95% CI 0.9 to 2.1), (40% OR = 3.5; 95% CI 1.2 to
10.6). A percentage of patients with general or ocular adverse
effects was lower in groups treated with latanoprost than in
other groups but observed differences were not statistically sig-
niﬁcant. CONCLUSIONS: Use of latanoprost in treatment of
POAG is more effective than the most frequent treatment pattern
in Poland.
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EFFECT OF CIRCADIAN INTRA-OCULAR PRESSURE
VARIATIONS ON THERAPEUTIC DECISION MAKING:
A MODELING APPROACH BASED ON A RANDOMIZED
CLINICAL TRIAL
Dubiner HB1, Berdeaux G2
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OBJECTIVES: The aim of our model was to estimate the effect
of circadian intra-ocular pressure (IOP) variations on ocular
hypertension diagnosis, treatment changes, nocturnal IOP peak
control, and daily cumulative pressure on the optic nerve head
(ONH). METHODS: Thirty-four glaucoma patients were
included in a double-masked randomized trial. Patients were
treated for 2 weeks with either travoprost 0.004% or latanoprost
0.005%, after a 4-week wash-out. Intra-ocular pressure was
measured every 4 hours during 1 day. The probability of reach-
ing a predeﬁned threshold (success) was calculated from a
normal function. Time spent over an IOP target was calculated
using area-under-the-curve weighted by success rate. The noc-
turnal IOP peak measure was estimated using a stepwise regres-
sion predicting the maximal night IOP as a function of day-time
IOP measures. Sensitivity analyses were performed. RESULTS:
Before treatment, IOP was more elevated in the morning than
the evening. The probability of an IOP exceeding the target value
of a diagnosis or therapy varied throughout the day. The IOP
variance was an important factor, regardless of the actual IOP
value. Travoprost controlled IOP better than latanoprost at
16:00 and 20:00. More patients (up to 34.5%) would reach the
IOP target with travoprost. Cumulative time spent above a target
IOP was lower (up to 2.7 hours) with travoprost. Diurnal IOP
measured at 16:00 was the single most predictive IOP measure
of nocturnal peaks. Travoprost would be better at controlling
these IOP ﬂuctuations (relative risk up to 1.34). CONCLU-
SIONS: The data suggest that 1) ocular hypertension diagnosis
and therapeutic decisions should be made early in the morning;
and 2) daily IOP control should protect against the deleterious
effects of cumulative pressure on the ONH and nocturnal IOP
peaks.
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A COST-EFFECTIVENESS ANALYSIS OF LATANOPROST IN
THE TREATMENT OF OPEN ANGLE GLAUCOMA IN SPAIN
Soto J, De Miguel V
Pﬁzer SA, Alcobendas, Madrid, Spain
OBJECTIVES: Glaucoma is a chronic disease and untreated
leads to progressive loss of vision. Latanoprost has shown good
